LGD-4033 vs Raloxifene
Moderate Research vs FDA Approved
avoid Mechanism-based · 64% Both LGD-4033 and Raloxifene carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.
Molecular Data
LGD-4033 Raloxifene
Weight 338.25 Da 473.58 Da
Half-life ~24-36 hours ~28 hours
Type Nonsteroidal selective androgen receptor modulator (C14H12F6N2O) Benzothiophene-derived selective estrogen receptor modulator
Key Benefits
LGD-4033
01 Strongest SARM for lean muscle mass accrual, with clinical trial data supporting dose-dependent increases in lean body mass
02 Tissue-selective action with minimal stimulation of the prostate and other androgen-sensitive tissues
03 Clinical evidence of improved physical function (leg press strength, stair-climbing speed) in hip fracture patients
04 No aromatization to estrogen (no estrogen-related water retention or gynecomastia at the receptor level)
05 No conversion to DHT (reduced risk of androgenic hair loss and prostate stimulation compared to testosterone)
06 Convenient once-daily oral dosing due to 24-36 hour half-life
07 Phase 2 clinical data available, providing a stronger evidence base than most other SARMs
Raloxifene
01 Superior breast tissue estrogen receptor antagonism makes it the preferred SERM for gynecomastia reversal
02 No estrogen agonist activity in the uterus, avoiding the endometrial risks associated with tamoxifen
03 Estrogen agonist activity in bone preserves bone mineral density and reduces fracture risk
04 Lower overall thromboembolic risk compared to tamoxifen
05 Metabolized via glucuronidation rather than CYP2D6, avoiding the drug interaction concerns that affect tamoxifen
06 Simple once-daily oral dosing with a manageable 28-hour half-life
07 FDA-approved with decades of clinical safety data in postmenopausal women
Side Effects
LGD-4033
Testosterone suppression (dose-dependent; more suppressive than Ostarine at equivalent doses, occurs in most users by week 4-6)
Water retention (non-estrogenic mechanism, typically mild to moderate, contributes to scale weight increase)
HDL cholesterol reduction (dose-dependent lipid impact observed in clinical trials)
Headaches (most common in the first 1-2 weeks, usually transient)
Fatigue or lethargy (related to testosterone suppression, typically becomes noticeable mid-cycle)
Reduced libido (related to HPG axis suppression, severity varies by dose and individual)
Raloxifene
Hot flashes and increased sweating
Leg cramps and muscle spasms
Joint pain or stiffness
Peripheral edema (mild swelling in extremities)
Flu-like symptoms during initial weeks
Contraindications
Pre-existing liver disease or elevated liver enzymes at baseline
Hormone-sensitive cancers (prostate cancer or other androgen-driven malignancies)
Pregnancy or potential pregnancy (teratogenic risk from androgen receptor agonism)
Breastfeeding
Age under 25 (incomplete endocrine system maturation and higher risk of HPG axis disruption)
Concurrent use of hepatotoxic medications without medical supervision
Known cardiovascular disease (insufficient long-term safety data for this population)
History of significant lipid abnormalities (LGD-4033 suppresses HDL)
History of deep vein thrombosis, pulmonary embolism, retinal vein thrombosis, or other venous thromboembolic events
Active or past history of stroke or transient ischemic attack
Known hypersensitivity to raloxifene hydrochloride or any excipients
Pregnancy or planned pregnancy (category X -- contraindicated)
Prolonged immobilization (e.g., post-surgical recovery, extended bed rest) due to elevated DVT risk
Severe hepatic impairment
Research Evidence
LGD-4033 Raloxifene
Status Moderate Research FDA Approved
References 5 studies 4 studies
Latest 2018 —
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.